These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Uses for immunofluorescence tests of skin and sera. Utilization of immunofluorescence in the diagnosis of bullous diseases, lupus erythematosus, and certain other dermatoses. Arch Dermatol; 1975 Mar; 111(3):371-81. PubMed ID: 1091215 [TBL] [Abstract][Full Text] [Related]
43. The immunofluorescent tumor imprint technique. IV. The significance of "thready" nuclear immunofluorescence. Burnham TK; Neblett TR; Fine G; Bank P Arch Dermatol; 1969 May; 99(5):611-6. PubMed ID: 4889089 [No Abstract] [Full Text] [Related]
44. Usefulness of direct immunofluorescence in patients with lupus erythematosus. Dahl MV Arch Dermatol; 1983 Dec; 119(12):1010-7. PubMed ID: 6360051 [No Abstract] [Full Text] [Related]
45. Clq deposits at the dermoepidermal junction: a marker discriminating for discoid and systemic lupus erythematosus. Leibowitch M; Droz D; Noël LH; Avril MF; Leibowitch J J Clin Immunol; 1981 Apr; 1(2):119-24. PubMed ID: 7037828 [TBL] [Abstract][Full Text] [Related]
46. The clinical significance of the in vivo antinuclear antibody phenomenon. Williams WV; Barjenbrach P; Adelstein E; Sharp GC; Walker SE Arch Pathol Lab Med; 1986 Sep; 110(9):798-802. PubMed ID: 3530186 [TBL] [Abstract][Full Text] [Related]
47. [Nature and significance of antinuclear immune globulins]. Zitnan D; Cebecauer L; Hajzok O; Bosmanský K Bratisl Lek Listy; 1968 Apr; 49(4):399-412. PubMed ID: 4175384 [No Abstract] [Full Text] [Related]
48. Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications. Chlebus E; Wolska H; Blaszczyk M; Jablonska S J Am Acad Dermatol; 1998 Mar; 38(3):405-12. PubMed ID: 9520021 [TBL] [Abstract][Full Text] [Related]
49. Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea. Oh EH; Kim EJ; Ro YS; Ko JY J Dermatol; 2018 Apr; 45(4):436-443. PubMed ID: 29423919 [TBL] [Abstract][Full Text] [Related]
51. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Chong BF; Song J; Olsen NJ Br J Dermatol; 2012 Jan; 166(1):29-35. PubMed ID: 21910708 [TBL] [Abstract][Full Text] [Related]
52. [Specificity of antinuclear autoantibodies in diseases with systemic destruction of connective tissue]. Shekhonin BV; Trusov OA; Butov IuS Biull Eksp Biol Med; 1977 Jul; 84(7):75-8. PubMed ID: 329917 [TBL] [Abstract][Full Text] [Related]
53. Circumscribed scleroderma with immunologic evidence of systemic lupus erythematosus. Mitchell AJ; Rusin LJ; Diaz LA Arch Dermatol; 1980 Jan; 116(1):69-73. PubMed ID: 6153258 [TBL] [Abstract][Full Text] [Related]
54. Triad of glomerulonephritis, antinuclear antibodies, and positive skin immunofluorescence. Variant of systemic lupus erythematosus. Ascer K; Walker JA; Lief PD; Barland P; Bank N Am J Med; 1983 Jan; 74(1):83-9. PubMed ID: 6336892 [TBL] [Abstract][Full Text] [Related]
55. Clinical significance of antinuclear antibodies in systemic lupus erythematosus. Liu HW; Chi CY; Lin SF; Tsai JH; Chen CY Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1981 Sep; 14(3):135-45. PubMed ID: 7026188 [TBL] [Abstract][Full Text] [Related]
56. Prognostic implications of active discoid lupus erythematosus and malar rash at the time of diagnosis of systemic lupus erythematosus: Results from a prospective cohort study. Drucker AM; Su J; Mussani F; Siddha SK; Gladman DD; Urowitz MB Lupus; 2016 Apr; 25(4):376-81. PubMed ID: 26453664 [TBL] [Abstract][Full Text] [Related]
57. [Immunofluorescent method in dermatology (review of the literature)]. Dobzhanskiĭ SI; Tabakova LS Vestn Dermatol Venerol; 1974 Aug; 0(8):13-8. PubMed ID: 4611090 [No Abstract] [Full Text] [Related]
58. Thyroid autoantibodies in the subsets of lupus erythematosus: correlation with other autoantibodies and thyroid function. Konstadoulakis MM; Kroubouzos G; Tosca A; Piperingos G; Marafelia P; Konstadoulakis M; Varelzidis A; Koutras DA Thyroidology; 1993 Apr; 5(1):1-7. PubMed ID: 7508737 [TBL] [Abstract][Full Text] [Related]
59. [Routine immunofluorescence examinations for the demonstration of antinuclear factors]. Hiemann D Z Gesamte Inn Med; 1969 Jan; 24(1):Suppl:150-1. PubMed ID: 4918616 [No Abstract] [Full Text] [Related]
60. Cutaneous lupus erythematosus--a study of clinical and laboratory prognostic factors in 65 patients. Healy E; Kieran E; Rogers S Ir J Med Sci; 1995; 164(2):113-5. PubMed ID: 7607834 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]